Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 263

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 19
Chunk 263
---
,000                3,500,000  
  Shares issued:                                                                                                              
  At the beginning of the year                                                            1,582,296                1,582,419  
  Exercise of stock options                              123                                               12                 
  Issuance of shares                                     —                                                             8,519  
  As of the end of the year                                                               1,582,419                1,590,950  

The shares issued by the Company are ordinary shares with no par value that have no restrictions on any rights.

The number of treasury shares included in the above shares issued was 27,767 13,405 17,300

The number of treasury shares as of April 1, 2023, March 31, 2024 and 2025 includes 6,215 5,888 5,565 520 847 460 783

During the year ended March 31, 2024, the Company conducted the disposal of 13,958 47,614

During the year ended March 31, 2025, the Company issued 8,519 7,327 18,064 18,064 24,999

The shares of the Company’s common stock and treasury shares were converted into the Company’s American Depositary Shares (“ ADSs”) and settled with employees.

During the year ended March 31, 2025, Takeda acquired a total of 11,544 49,978 23,367 99,956

  Dividends declared and paid                        Dividends per share JPY      Record date             Effective date    
  April 1, 2022, to March 31, 2023                                                                                          
  Q1 2022                               140,365                            ¥      March 31, 2022          June 30, 2022     
  April 1, 2023, to March 31, 2024                                                                                          
  April 1, 2024, to March 31, 2025                                                                                          
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Q3 2022                               140,474                        90.00      September 30, 2022      December 1, 2022  
  Q1 2023                               140,475                        90.00      March 31, 2023          June 29, 2023     
  Q3 2023